Bicycle Therapeutics (BCYC) Current Deferred Revenue (2018 - 2026)

Bicycle Therapeutics has reported Current Deferred Revenue for 9 years, with the latest figure at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 77.68% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (down 77.68% YoY), and the FY2025 full-year result was $3.0 million, down 97.09% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $2.8 million, down from $3.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $135.2 million in Q4 2023, with the low at $1.2 million in Q2 2022.
• Historically, Current Deferred Revenue has averaged $26.0 million across 5 years, with a median of $12.5 million in 2025.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue jumped 1726.95% — and 2025, when it slumped 97.09%.
• Bicycle Therapeutics' Current Deferred Revenue stood at $7.4 million in 2022, then jumped by 1726.95% to $135.2 million in 2023, then declined by 24.81% to $101.7 million in 2024, then tumbled by 97.09% to $3.0 million in 2025, then dropped by 5.61% to $2.8 million in 2026.
• The last three Current Deferred Revenue figures came in at $2.8 million (Q1 2026), $3.0 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.